FOXP3 and CXCR4-positive regulatory T cells in the tumor stroma as indicators of tumor immunity in the conjunctival squamous cell carcinoma microenvironment.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2022
Historique:
received: 02 07 2021
accepted: 22 01 2022
entrez: 31 3 2022
pubmed: 1 4 2022
medline: 15 4 2022
Statut: epublish

Résumé

Conjunctival squamous cell carcinoma (SCC) is the most common ocular surface neoplasia. The purpose of this retrospective study was to examine the role of regulatory T cell (Treg) activity in tumor immunity and investigate the tumor microenvironment as a new treatment focus in conjunctival SCC. Cancer progression gene array and immunohistochemical analyses of FOXP3 as a Treg marker, CD8 as a tumor-infiltrating lymphocyte marker, and CXCR4 expression on activated Tregs were conducted in a series of 31 conjunctival SCC cases. The objective was to investigate the immunoreactive response in tumor cells and stromal cells in the cancer microenvironment. The stroma ratio in tumor cells was investigated by monitoring α-smooth muscle actine (SMA) expression between carcinoma in situ (Tis) and advanced carcinoma (Tadv) (P<0.01). No significant change in PD-L1 expression was observed in this study (P = 0.15). Staining patterns of FOXP3, CD8, and CXCR4 were examined separately between tumor cells and stromal cells in SCC tumors. Differences in staining of FOXP3 in Tregs and CD8 in tumor-infiltrating lymphocytes in tumor stroma in the Tis group were observed compared with the Tadv group (each P<0.01). In addition, double immunostaining of CXCR4/FOXP3 was correlated with progression-free survival (P = 0.049). Double immunostaining of CXCR4/FOXP3 correlated with American Joint Committee on Cancer T-stage, independent of age or Ki67 index (P<0.01). Our results show that FOXP3 and the CXCR4/FOXP3 axis are important pathologic and prognostic factors of ocular surface neoplasia, including SCC. The tumor microenvironment of conjunctival SCC should be considered in the future development of treatment options.

Identifiants

pubmed: 35358193
doi: 10.1371/journal.pone.0263895
pii: PONE-D-21-21699
pmc: PMC8970378
doi:

Substances chimiques

CXCR4 protein, human 0
FOXP3 protein, human 0
Forkhead Transcription Factors 0
Receptors, CXCR4 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0263895

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Science. 2003 Feb 14;299(5609):1057-61
pubmed: 12522256
Blood. 2014 Jul 17;124(3):374-84
pubmed: 24914139
Nat Rev Immunol. 2009 Mar;9(3):162-74
pubmed: 19197294
Eye (Lond). 2019 Feb;33(2):283-294
pubmed: 30593587
PLoS One. 2014 Oct 23;9(10):e110928
pubmed: 25340823
Clin Cancer Res. 2008 Aug 15;14(16):5220-7
pubmed: 18698040
Cornea. 2013 Oct;32(10):1354-8
pubmed: 23974890
Graefes Arch Clin Exp Ophthalmol. 2021 Oct;259(10):3127-3136
pubmed: 34050808
Cancer Immunol Immunother. 2021 Jul;70(7):1907-1915
pubmed: 33398391
Eur J Immunol. 2010 Jul;40(7):1830-5
pubmed: 20583029
Nature. 2015 Jul 9;523(7559):231-5
pubmed: 25970248
N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
Cancer Res. 2009 Mar 1;69(5):2000-9
pubmed: 19244125
J Immunol. 1999 Nov 15;163(10):5211-8
pubmed: 10553041
Future Oncol. 2020 Feb;16(4):11-19
pubmed: 31951149
Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12293-7
pubmed: 12218188
Lancet Oncol. 2017 Aug;18(8):1104-1115
pubmed: 28651929
J Exp Med. 2011 Jul 4;208(7):1367-76
pubmed: 21708926
Sci Rep. 2020 Jun 9;10(1):9292
pubmed: 32518311
Invest Ophthalmol Vis Sci. 2019 May 1;60(6):2388-2398
pubmed: 31141610
Cancer Epidemiol Biomarkers Prev. 1997 Feb;6(2):73-7
pubmed: 9037556
Surv Ophthalmol. 1995 May-Jun;39(6):429-50
pubmed: 7660300
Rom J Morphol Embryol. 2019;60(2):455-461
pubmed: 31658318
Hum Pathol. 2019 Dec;94:92-97
pubmed: 31493427
Appl Immunohistochem Mol Morphol. 2018 Jul;26(6):e70-e76
pubmed: 29489511
Int J Cancer. 2010 Aug 15;127(4):759-67
pubmed: 20518016
Breast Cancer Res. 2011 Apr 26;13(2):R47
pubmed: 21521526
J Immunol. 2009 Feb 1;182(3):1247-52
pubmed: 19155469
Proc Natl Acad Sci U S A. 2013 Oct 29;110(44):17945-50
pubmed: 24127572
J Clin Oncol. 2020 Sep 10;38(26):3051-3061
pubmed: 32730186
Nat Med. 1996 Oct;2(10):1096-103
pubmed: 8837607
Cell. 2015 Sep 24;163(1):160-73
pubmed: 26406376
J Clin Epidemiol. 1996 Dec;49(12):1373-9
pubmed: 8970487
Science. 1996 Mar 22;271(5256):1734-6
pubmed: 8596936

Auteurs

Mizuki Tagami (M)

Department of Ophthalmology and Visual Sciences, Graduate School of Medicine, Osaka City University, Osaka, Japan.
Ophthalmology Department and Eye Center, Kobe Kaisei Hospital, Kobe, Hyogo, Japan.

Anna Kakehashi (A)

Department of Molecular Pathology, Graduate School of Medicine, Osaka City University, Osaka, Japan.

Atsuko Katsuyama-Yoshikawa (A)

Ophthalmology Department and Eye Center, Kobe Kaisei Hospital, Kobe, Hyogo, Japan.
Division of Ophthalmology, Department of Surgery, Kobe University Graduate School of Medicine, Hyogo, Japan.

Norihiko Misawa (N)

Department of Ophthalmology and Visual Sciences, Graduate School of Medicine, Osaka City University, Osaka, Japan.

Atsushi Sakai (A)

Department of Ophthalmology and Visual Sciences, Graduate School of Medicine, Osaka City University, Osaka, Japan.

Hideki Wanibuchi (H)

Department of Molecular Pathology, Graduate School of Medicine, Osaka City University, Osaka, Japan.

Atsushi Azumi (A)

Ophthalmology Department and Eye Center, Kobe Kaisei Hospital, Kobe, Hyogo, Japan.

Shigeru Honda (S)

Department of Ophthalmology and Visual Sciences, Graduate School of Medicine, Osaka City University, Osaka, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH